Healthcare Investing in 2026: iShares Global Healthcare ETF Outperforms Invesco Health Care ETF
2026-07-16 13:31
•Sarah Sidlow •The Motley Fool
•••• ••••• Axe Capital view
Why Global Healthcare ETFs Matter for JSE Investors in 2026
iShares Global Healthcare ETF shows stronger returns and less volatility than Invesco’s equally weighted healthcare fund.
Healthcare often flies under the radar on the JSE, but international healthcare ETFs like iShares Global Healthcare (IXJ) are quietly outperforming. IXJ’s focus on market-cap weighting and broad global exposure, spanning 110 stocks, delivers not just higher dividends but also lower volatility compared to Invesco’s equal-weight strategy, which splits its 60 holdings evenly. This means less sharp drops and steadier returns. For South African investors, this matters because our local healthcare names are limited, so international diversification through IXJ presents a neat way to gain stable, long-term growth. Eli Lilly, Johnson & Johnson, and AbbVie—heavyweights in IXJ—drive this steady performance. At the same time, rand weakness often tailors your actual returns, so watch USD/ZAR closely when adding offshore healthcare exposure. The view could be wrong if regulatory changes or global healthcare disruptions hit these large pharma companies hard. this is just my opinion and not financial advice
I’d buy into the iShares Global Healthcare ETF for a stable, dividend-yielding complement to JSE holdings, keeping an eye on rand fluctuations. Avoid the Invesco equal-weight healthcare ETF for now given its weaker risk-return profile.
- iShares Global Healthcare ETF (IXJ)
- USD/ZAR
- Regulatory risks impacting global pharma companies
- Rand volatility affecting offshore returns
7/10
The iShares Global Healthcare ETF (IXJ) outperformed the Invesco S&P 500 Equal Weight Health Care ETF (RSPH) over the past five years, delivering stronger total returns (1.50% dividend yield vs. 0.70%), lower volatility (beta of 0.56 vs. 0.78), and a shallower maximum drawdown. While both funds charge identical 0.40% expense ratios, IXJ's market-cap weighting and international exposure of 110 global healthcare stocks provide broader diversification compared to RSPH's 60 U.S. large-cap equal-weighted holdings.
This article was originally published by The Motley Fool and has been adapted here for Axe Capital Trading News.
Publisher: The Motley Fool
Author: Sarah Sidlow
Categories: Rates, Equities, Capital Returns, Healthcare
Tickers: IXJ, RSPH, LLY, JNJ, ABBV
Sentiment: Positive - IXJ demonstrated superior performance with higher 5-year total returns ($1,257 vs. $1,177), lower volatility (beta 0.56), lower maximum drawdown (18.1% vs. 22%), double the dividend yield (1.50% vs. 0.70%), and significantly higher AUM ($4.1B vs. $734.1M), making it the more compelling choice for most healthcare investors. RSPH offers a valid alternative approach with equal-weighting that reduces concentration risk and provides more balanced sector exposure across healthcare subsectors. However, it underperformed IXJ on returns and volatility metrics, though it may appeal to defensive investors seeking exposure to healthcare providers and services.
Keywords: healthcare ETF, market-cap weighting, equal-weight strategy, dividend yield, volatility, international exposure, diversification
Insights:
- IXJ: Positive: IXJ demonstrated superior performance with higher 5-year total returns ($1,257 vs. $1,177), lower volatility (beta 0.56), lower maximum drawdown (18.1% vs. 22%), double the dividend yield (1.50% vs. 0.70%), and significantly higher AUM ($4.1B vs. $734.1M), making it the more compelling choice for most healthcare investors.
- RSPH: Neutral: RSPH offers a valid alternative approach with equal-weighting that reduces concentration risk and provides more balanced sector exposure across healthcare subsectors. However, it underperformed IXJ on returns and volatility metrics, though it may appeal to defensive investors seeking exposure to healthcare providers and services.
- LLY: Positive: Eli Lilly is highlighted as a major holding (10.6%) in the outperforming IXJ fund, contributing to its strong performance as a pharma leader.